Get the Stockscreener App
4.94
0.71%
-0.00
Passage Bio Inc stock is traded at $4.94, with a volume of 16,545.
It is down -0.71% in the last 24 hours and up +4.36% over the past month.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
See More
Previous Close:
$4.94
Open:
$4.85
24h Volume:
16,545
Relative Volume:
0.19
Market Cap:
$15.63M
Revenue:
-
Net Income/Loss:
$-37.68M
P/E Ratio:
-0.4174
EPS:
-11.8364
Net Cash Flow:
$-30.65M
1W Performance:
+1.98%
1M Performance:
+4.36%
6M Performance:
-61.07%
1Y Performance:
-34.07%
1-Day Range:
$4.79
$4.95
1-Week Range:
$4.60
$5.00
52-Week Range:
$3.29
$20.00
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
4.865 | 15.87M | 0 | -37.68M | -30.65M | -11.84 |
VRTX
Vertex Pharmaceuticals Inc
|
485.15 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
674.16 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
907.15 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.28 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.62 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Apr-21-26 | Downgrade | TD Cowen | Buy → Hold |
| Apr-21-26 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-31-26 | Initiated | Oppenheimer | Outperform |
| Feb-10-26 | Resumed | Chardan Capital Markets | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
Passage Bio Inc (PASG) Cash Flow - TradingKey
Passage Bio Inc (PASG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Passage Bio Inc (PASG) Institutional Confidence - TradingKey
Passage Bio Inc (PASG) Income Statement - TradingKey
Passage Bio Inc (PASG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Passage Bio Inc (PASG) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
PASG|Passage Bio Inc|Price:4.940|Chg%:+0.040 - TradingKey
Passage Bio Inc (PASG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Passage Bio Inc (PASG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Passage Bio Inc (PASG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Passage Bio, Inc. Revenue Breakdown – NASDAQ:PASG - TradingView
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—CRNX, SLP, NCSM, and PASG - Morningstar
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CRNX, SLP, NCSM, and PASG - Finansavisen
PASG Q2'26 Earnings: revenue estimate is 0 USD - TradingView
PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Stocktwits
Passage Bio (PASG) to merge with Remix in $100M-backed oncology deal - Stock Titan
Form 4 Passage Bio Inc For: 22 July By Investing.com - Investing.com Nigeria
Passage Bio (NASDAQ: PASG) to merge with Remix Therapeutics in $346M stock deal - Stock Titan
Layoff Tracker: EMD Serono may trim R&D workforce by up to 70 - BioSpace
Passage Bio eyes gene therapy progress as Nasdaq-listed biotech develops CNS pipeline - Ad Hoc News
Passage Bio Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 7.3%Debt Analysis Report - dars.gov.et
Passage Bio Inc. (PASG) Rises 7.3% as Momentum Lifts Shares Above Key SupportElliott Wave Count - DonanımHaber
Passage Bio (PASG) Surges 7.3% as Stock Tests Key Resistance at $5.25Sentiment Divergence - DonanımHaber
Passage Bio focuses on genetic medicine strategy as investors weigh long-term potential - ad-hoc-news.de
PASG Q1 2026 Earnings: Narrowed Losses Beat Estimates as Clinical Progress ContinuesNegative Surprise Momentum - dars.gov.et
SPRY, PASG, BOXL: Why these stocks plunged double digits in after-hours trading today - MSN
Lynx1 Capital Management LP Increases Stake in Passage Bio Inc - GuruFocus
Passage Bio, Inc. Financial Disclosures & SEC Filings - TradingView
Passage Bio explores gene therapy potential as investors weigh long-term prospects - AD HOC NEWS
Deal Watch: Boehringer Ingelheim Unveils Cancer Pacts With Immunai And Combotope - insights.citeline.com
Passage Bio (PASG) Stock Analysis Report | Financials & Insights - Benzinga
Lynx1 Capital Management Discloses Investment at Passage BIO with 21.0% Stake - TradingView
Passage BIO (NASDAQ: PASG) holder Lynx1 reports 21% ownership amid Remix deal - Stock Titan
Passage Bio (PASG) Slides 6% as Shares Test Key Support Near $4.35AD Line Divergence - dars.gov.et
PASGPassage Bio Inc Latest SEC Filings - Finviz
Latham & Watkins Advises Remix Therapeutics in Merger With Passage Bio - Legal Desire Media and Insights
Passage Bio (PASG) holder adds 50,055 shares in open-market buy - Stock Titan
Passage Bio to Merge With Remix in Deal Backed by $100 Million Financing - MyChesCo
PASG Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock Up 8.55%Profit Announcement - dars.gov.et
Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired - RTTNews
Passage Bio, Inc. Actuals & Estimates (NASDAQ:PASG) - TradingView
Enterprise value to EBIT forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Price to sales forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Price to book forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Price to earnings forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Enterprise value to EBITDA forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Enterprise value to revenue forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Passage Bio, Inc. Actuals & Estimates (BOATS:PASG) - TradingView
Baselake Partners (PASG) reports 235,058 shares, 7.3% ownership - Stock Titan
Remix Therapeutics secures $100M and a reverse merger - The Business Journals
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.58%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):